Management of relapsed ovarian cancer: a review-Reference-Cited by-同舟云学术

Management of relapsed ovarian cancer: a review

Published:2016-07-28 Issue:1 Volume:5 Page:
ISSN:2193-1801
Container-title:SpringerPlus
language:en
Short-container-title:SpringerPlus

Author:

Giornelli Gonzalo H.

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

http://link.springer.com/content/pdf/10.1186/s40064-016-2660-0.pdf

Reference73 articles.

1. Aghajanian C, Goff B, Nycum LR (2015) Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer. Gynecol Oncol 139(1):10–16

2. AGO Study Group (2015) Study comparing tumor debulking surgery versus chemotherapy alone in recurrent platinum-sensitive ovarian cancer (DESKTOP III). ClinicalTrials.gov Identifier: NCT01166737. https://clinicaltrials.gov/ct2/show/NCT01166737?term=NCT01166737&rank=1 . Accessed Jan 2016

3. Alsop K, Fereday S, Meldrum C (2012) CA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol 30(21):2654–2663

4. Armstrong DK, Bundy B, Wenzel L (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354(1):34–43

5. Audeh MW, Carmichael J, Penson RT (2010) Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 376(9737):245–251

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Annonaceae acetogenins: A potential treatment for gynecological and breast cancer;Fitoterapia;2024-10

2. Overview of BH3 mimetics in ovarian cancer;Cancer Treatment Reviews;2024-09

3. Cell-intrinsic platinum response and associated genetic and gene expression signatures in ovarian cancer cell lines and isogenic models;2024-07-29

4. Comparing niraparib versus platinum-taxane doublet chemotherapy as neoadjuvant treatment in patients with newly diagnosed homologous recombination–deficient stage III/IV ovarian cancer: study protocol for cohort C of the open-label, phase 2, randomized controlled multicenter OPAL trial;Trials;2024-05-04